Adjuvant systemic therapy in older women with breast cancer

References

• SEER Cancer Statistics Factsheets: Breast CancerBethesda, MDNational Cancer Institute2015
   Google Scholar
• OrtmanJMVelkoffVAHowardHAn aging nation: the older population in the United StatesWashington, DCUS Census Bureau2014
   Google Scholar
• SmithBDSmithGLHurriaAHortobagyiGNBuchholzTAFuture of cancer incidence in the United States: burdens upon an aging, changing nationJ Clin Oncol200927172758276519403886
   PubMed Web of Science ®Google Scholar
• LavelleKToddCMoranAHowellABundredNCampbellMNon-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 yearsBr J Cancer20079681197120317387342
   PubMed Web of Science ®Google Scholar
• GiordanoSHHortobagyiGNKauSWTheriaultRLBondyMLBreast cancer treatment guidelines in older womenJ Clin Oncol200523478379115681522
   PubMed Web of Science ®Google Scholar
• HershmanDLShaoTKushiLHEarly discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Res Treat2011126252953720803066
   PubMed Web of Science ®Google Scholar
• BouchardyCRapitiEFiorettaGUndertreatment strongly decreases prognosis of breast cancer in elderly womenJ Clin Oncol200321193580358712913099
   PubMed Web of Science ®Google Scholar
• DiabSGElledgeRMClarkGMTumor characteristics and clinical outcome of elderly women with breast cancerJ Natl Cancer Inst200092755055610749910
   PubMed Web of Science ®Google Scholar
• BiganzoliLWildiersHOakmanCManagement of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)Lancet Oncol2012134e148e16022469125
   PubMed Web of Science ®Google Scholar
• OwusuCLashTLSillimanRAEffectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancerBreast J200713437438217593042
   PubMed Web of Science ®Google Scholar
• ColleoniMGiobbie-HurderAReganMMAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1–98 studyJ Clin Oncol20112991117112421321298
   PubMed Web of Science ®Google Scholar
• ForbesJFCuzickJBuzdarAHowellATobiasJSBaumMEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol200891455318083636
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• MussHBTuDIngleJNEfficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17J Clin Oncol200826121956196418332474
   PubMed Web of Science ®Google Scholar
• AmirESerugaBNiraulaSCarlssonLOcanaAToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysisJ Nati Cancer Inst20111031712991309
   PubMed Web of Science ®Google Scholar
• SenkusEKyriakidesSPenault-LlorcaFPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followupAnn Oncol201324Suppl 6vi7vi2323970019
   PubMed Web of Science ®Google Scholar
• ZillerVKalderMAlbertUSAdherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnn Oncol200920343143619150950
   PubMed Web of Science ®Google Scholar
• SestakICuzickJSapunarFRisk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisLancet Oncol20089986687218703382
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• NeunerJMYenTWSparapaniRALaudPWNattingerABFracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patientsOsteoporosis Int2011221128472855
   Web of Science ®Google Scholar
• EidtmannHde BoerRBundredNEfficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyAnn Oncol201021112188219420444845
   PubMed Web of Science ®Google Scholar
• KoopalCJanssen-HeijnenMLvan de WouwAJvan den BerghJPFracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancerBreast201524215315825618224
   PubMed Web of Science ®Google Scholar
• ColemanRPowlesTPatersonAAdjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsLancet2015386100011353136126211824
   PubMed Web of Science ®Google Scholar
• GnantMPfeilerGDubskyPCAdjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialLancet2015386999243344326040499
   PubMed Web of Science ®Google Scholar
• HindDWyldLBeverleyCBReedMWSurgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)Cochrane Database Syst Rev2006251CD00427216437480
   PubMedGoogle Scholar
• DixonJMRenshawLMacaskillEJIncrease in response rate by prolonged treatment with neoadjuvant letrozoleBreast Cancer Res Treat2009113114515118264759
   PubMed Web of Science ®Google Scholar
• ChatzidakiPMellosCBrieseVMylonasIPerioperative complications of breast cancer surgery in elderly women (>/=80 years)Ann Surg Oncol201118492393121107743
   PubMed Web of Science ®Google Scholar
• HindDWyldLReedMWSurgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane reviewBr J Cancer20079671025102917285133
   PubMed Web of Science ®Google Scholar
• ChristiansenPBjerreKEjlertsenBMortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in DenmarkJ Natl Cancer Inst2011103181363137221881042
   PubMedGoogle Scholar
• SchlenkEADunbar-JacobJEngbergSMedication non-adherence among older adults: a review of strategies and interventions for improvementJ Gerontol Nurs2004307334315287325
   PubMedGoogle Scholar
• HershmanDLKushiLHShaoTEarly discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsJ Clin Oncol201028274120412820585090
   PubMed Web of Science ®Google Scholar
• GuthUMyrickMEKandlerCVetterMThe use of adjuvant endocrine breast cancer therapy in the oldest oldBreast201322586386823541734
   PubMed Web of Science ®Google Scholar
• RavdinPMSiminoffLADavisGJComputer program to assist in making decisions about adjuvant therapy for women with early breast cancerJ Clin Oncol200119498099111181660
   PubMed Web of Science ®Google Scholar
• WishartGCBajdikCDDicksEPREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2Br J Cancer2012107580080722850554
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• FanCOhDSWesselsLConcordance among gene-expression-based predictors for breast cancerN Engl J Med2006355656056916899776
   PubMed Web of Science ®Google Scholar
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• JonesSHolmesFAO’ShaughnessyJDocetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735J Clin Oncol20092781177118319204201
   PubMed Web of Science ®Google Scholar
• MartinMRodriguez-LescureARuizARandomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancerJ Natl Cancer Inst20081001180581418505968
   PubMedGoogle Scholar
• SparanoJAWangMMartinoSWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358161663167118420499
   PubMed Web of Science ®Google Scholar
• MussHBBerryDACirrincioneCTAdjuvant chemotherapy in older women with early-stage breast cancerN Engl J Med2009360202055206519439741
   PubMed Web of Science ®Google Scholar
• PooleCJEarlHMHillerLEpirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancerN Engl J Med2006355181851186217079759
   PubMed Web of Science ®Google Scholar
• MussHBWoolfSBerryDAdjuvant chemotherapy in older and younger women with lymph node-positive breast cancerJAMA200529391073108115741529
   PubMed Web of Science ®Google Scholar
• DoyleJJNeugutAIJacobsonJSGrannVRHershmanDLChemotherapy and cardiotoxicity in older breast cancer patients: a population-based studyJ Clin Oncol200523348597860516314622
   PubMed Web of Science ®Google Scholar
• WolffACBlackfordALVisvanathanKRisk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experienceJ Clin Oncol201533434034825534386
   PubMed Web of Science ®Google Scholar
• HowardRAGilbertESChenBELeukemia following breast cancer: an international population-based study of 376,825 womenBreast Cancer Res Treat2007105335936817221155
   PubMed Web of Science ®Google Scholar
• FargeotPBonneterreJRocheHDisease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trialJ Clin Oncol200422234622463015505276
   PubMed Web of Science ®Google Scholar
• KornblithABLanLArcherLQuality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907J Clin Oncol20112981022102821300923
   PubMed Web of Science ®Google Scholar
• PerroneFNuzzoFDi RellaFWeekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialAnn Oncol201526467568225488686
   PubMed Web of Science ®Google Scholar
• von MinckwitzGConradBReimerTA randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)Cancer2015121203639364826111104
   PubMed Web of Science ®Google Scholar
• BalducciLAl-HalawaniHCharuVElderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastimOncologist200712121416142418165618
   PubMed Web of Science ®Google Scholar
• BarcenasCHNiuJZhangNRisk of hospitalization according to chemotherapy regimen in early-stage breast cancerJ Clin Oncol201432192010201724868022
   PubMed Web of Science ®Google Scholar
• HoogerduijnJGBuurmanBMKorevaarJCGrobbeeDEde RooijSESchuurmansMJThe prediction of functional decline in older hospitalised patientsAge Ageing201241338138722378613
   PubMed Web of Science ®Google Scholar
• ExtermannMBolerIReichRRPredicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) scoreCancer2012118133377338622072065
   PubMed Web of Science ®Google Scholar
• FriedTRBradleyEHTowleVRAlloreHUnderstanding the treatment preferences of seriously ill patientsN Engl J Med2002346141061106611932474
   PubMed Web of Science ®Google Scholar
• MolinoAGiovanniniMAuriemmaAPathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancerCrit Rev Oncol Hematol200659322623316533603
   PubMed Web of Science ®Google Scholar
• DaidoneMGCoradiniDMartelliGVeneroniSPrimary breast cancer in elderly women: biological profile and relation with clinical outcomeCrit Rev Oncol Hematol200345331332512633842
   PubMed Web of Science ®Google Scholar
• MustacchiGCazzanigaMEPronzatoPDe MatteisADi CostanzoFFlorianiIBreast cancer in elderly women: a different reality? Results from the NORA studyAnn Oncol200718699199617351258
   PubMed Web of Science ®Google Scholar
• EngelsCCKiderlenMBastiaannetEThe clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysisBreast Cancer Res Treat2016156236137026968397
   PubMed Web of Science ®Google Scholar
• MussHBComing of age: breast cancer in seniorsOncologist201015Suppl 5576521138956
   PubMed Web of Science ®Google Scholar
• BoekhoutAHBeijnenJHSchellensJHTrastuzumabOncologist201116680081021632460
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• JoensuuHKellokumpu-LehtinenPLBonoPAdjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med2006354880982016495393
   PubMed Web of Science ®Google Scholar
• SpielmannMRocheHDelozierTTrastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialJ Clin Oncol200927366129613419917839
   PubMed Web of Science ®Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet20073699555293617208639
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNESequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancerJ Clin Oncol201129344491449722042958
   PubMed Web of Science ®Google Scholar
• TolaneySMBarryWTDangCTAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerN Engl J Med2015372213414125564897
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol200523317811781916258083
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol20082681231123818250349
   PubMed Web of Science ®Google Scholar
• RussellSDBlackwellKLLawrenceJIndependent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trialsJ Clin Oncol201028213416342120530275
   PubMed Web of Science ®Google Scholar
• SuterTMProcterMvan VeldhuisenDJTrastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialJ Clin Oncol200725253859386517646669
   PubMed Web of Science ®Google Scholar
• GoldhirschAGelberRDPiccart-GebhartMJ2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialLancet201338298971021102823871490
   PubMed Web of Science ®Google Scholar
• PivotXSuterTNabholtzJMCardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III studyEur J Cancer201551131660166626163096
   PubMed Web of Science ®Google Scholar
• SawakiMTokudomeNMizunoTEvaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]Jpn J Clin Oncol201141570971221355003
   PubMed Web of Science ®Google Scholar